GMO GlobalSign Holdings K.K.
GMO GlobalSign Holdings K.K. (3788.T) Financial Performance & Income Statement Overview
Review GMO GlobalSign Holdings K.K. (3788.T) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
GMO GlobalSign Holdings K.K. (3788.T) Income Statement & Financial Overview
Review GMO GlobalSign Holdings K.K. 3788.T income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $4.91B | $5.09B | $4.50B | $4.85B |
| Cost of Revenue | $1.99B | $2.004B | $1.89B | $1.99B |
| Gross Profit | $2.92B | $3.09B | $2.62B | $2.86B |
| Gross Profit Ratio | $0.60 | $0.61 | $0.58 | $0.59 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $2.64B | $2.66B | $2.55B | $2.50B |
| Operating Expenses | $2.64B | $2.66B | $2.55B | $2.54B |
| Total Costs & Expenses | $4.62B | $4.66B | $4.43B | $4.52B |
| Interest Income | $12.67M | $0.00 | $0.00 | $9.24M |
| Interest Expense | $6.91M | $0.00 | $0.00 | $5.91M |
| Depreciation & Amortization | $422.55M | $394.50M | $307.75M | $384.01M |
| EBITDA | $713.10M | $826.50M | $377.75M | $705.22M |
| EBITDA Ratio | $0.15 | $0.16 | $0.08 | $0.15 |
| Operating Income | $285.17M | $431.00M | $71.00M | $321.21M |
| Operating Income Ratio | $0.06 | $0.08 | $0.02 | $0.07 |
| Other Income/Expenses (Net) | -$1.53M | $22.00M | -$38.00M | -$11.42M |
| Income Before Tax | $283.64M | $453.00M | $33.00M | $309.79M |
| Income Before Tax Ratio | $0.06 | $0.09 | $0.007 | $0.06 |
| Income Tax Expense | $79.81M | $123.00M | $11.00M | $135.77M |
| Net Income | $202.41M | $326.00M | $21.00M | $172.67M |
| Net Income Ratio | $0.04 | $0.06 | $0.005 | $0.04 |
| EPS | $17.63 | $28.35 | $1.82 | $14.99 |
| Diluted EPS | $17.63 | $28.35 | $1.82 | $14.99 |
| Weighted Avg Shares Outstanding | $11.48M | $11.50M | $11.52M | $11.52M |
| Weighted Avg Shares Outstanding (Diluted) | $11.48M | $11.50M | $11.52M | $11.52M |
Financial performance has remained strong, with revenue growing from $4.85B in Q2 2024 to $4.91B in Q1 2025. Gross profit continued to perform well, with margins at 60% in the latest quarter. Operating income reached $285.17M in Q1 2025, holding a steady 6% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $713.10M. Net income dropped to $202.41M, keeping EPS at $17.63. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan